StageZero Life Sciences Ltd (TSE:SZLS) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
StageZero Life Sciences Ltd., known for its groundbreaking multi-cancer diagnostic test, Aristotle, is actively working to complete the payment of audit fees necessary to file its full year 2023 financials after a delay caused by financial constraints. The company is under a Failure to File Cease Trade Order, which prohibits trading until the financials are filed and the order is revoked, but confirms that there is no undisclosed material information.
For further insights into TSE:SZLS stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue